Merck fails to resurrect its $2.5B hep C patent win as appeals court rules for Gilead

31st October 2019 Uncategorised 0

Merck and Gilead Sciences have been battling over hepatitis C drug patents for years, and at one point, Merck thought it had won—to the tune of a multibillion-dollar jury verdict. But Gilead managed to turn that win into a loss, and Merck’s latest bid to revive it has fallen short.

More: Merck fails to resurrect its .5B hep C patent win as appeals court rules for Gilead
Source: fierce